CompareMarketResearchRequest a sample
Home / Healthcare / Nanomedicine

Healthcare · Market report

Nanomedicine Market Size, Share and Forecast 2026-2036

The global nanomedicine market is worth USD 20.1 bn in 2026 and is forecast to reach USD 47.5 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Lipid nanoparticles is the largest by platform segment.

USD 20.1 bnMarket size 2026
USD 47.5 bnForecast 2036
9.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global nanomedicine market is worth USD 20.1 bn in 2026 and is forecast to reach USD 47.5 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Lipid nanoparticles is the largest by platform segment.

ScopeMedicines and imaging agents built on nanoparticle carriers: lipid nanoparticle vaccines and RNA drugs, albumin-bound and liposomal cancer drugs, iron oxide nanoparticles and nanocrystal formulations.
IndustryHealthcare
Value 2025USD 18.5 bn
Value 2026USD 20.1 bn
Value 2036USD 47.5 bn
CAGR 2026-20369.0%
Volume 2026238 million doses
Volume 2036535 million doses
Average price 2026USD 84.5 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Nanomedicine market size and forecast, 2026-2036

Exhibit 1The global nanomedicine market is forecast to grow from USD 20.1 bn in 2026 to USD 47.5 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 9.0%
Nanomedicine market value, 2025 to 2036Market value by year. 2025: USD 18.5 bn; 2026: USD 20.1 bn; 2027: USD 21.9 bn; 2028: USD 23.8 bn; 2029: USD 26.0 bn; 2030: USD 28.3 bn; 2031: USD 30.9 bn; 2032: USD 33.7 bn; 2033: USD 36.7 bn; 2034: USD 40.0 bn; 2035: USD 43.6 bn; 2036: USD 47.5 bn. Compound annual growth rate 2026 to 2036: 9.0%.202520.1 bn202630.9 bn203147.5 bn20369.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 20.1 bn
2027USD 21.9 bn
2028USD 23.8 bn
2029USD 26.0 bn
2030USD 28.3 bn
2031USD 30.9 bn
2032USD 33.7 bn
2033USD 36.7 bn
2034USD 40.0 bn
2035USD 43.6 bn
2036USD 47.5 bn

Nanomedicine market segmentation

By platform

Exhibit 2Lipid nanoparticles is the largest segment by platform, with 36.0% of 2026 revenueEstimated share of 2026 global revenue, by platform
Nanomedicine market share by platform, 2026Share of 2026 revenue by platform. Lipid nanoparticles: 36.0%; Liposomes: 22.0%; Iron-based nanoparticles: 18.0%; Albumin-bound particles: 12.0%; Nanocrystals and polymeric: 12.0%.Lipid nanoparticles36.0%Liposomes22.0%Iron-based nanoparticles18.0%Albumin-bound particles12.0%Nanocrystals and polymeric12.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Lipid nanoparticles36.0%35.8%USD 7.2 bn8.9%
Liposomes22.0%20.9%USD 4.4 bn8.4%
Albumin-bound particles12.0%9.0%USD 2.4 bn5.9%
Iron-based nanoparticles18.0%18.7%USD 3.6 bn9.4%
Nanocrystals and polymeric12.0%15.7%USD 2.4 bn11.9%

By application

Exhibit 3Genetic and rare disease adds the most revenue by application, growing from USD 4.2 bn in 2026 to USD 13.8 bn by 2036Estimated revenue in USD by application, 2026 and 2036 forecast
Nanomedicine market by application, 2026 and 2036Revenue by application in 2026 and 2036. Oncology: USD 6.8 bn in 2026, USD 15.6 bn in 2036, change +128%; Genetic and rare disease: USD 4.2 bn in 2026, USD 13.8 bn in 2036, change +227%; Infectious disease vaccines: USD 5.2 bn in 2026, USD 9.9 bn in 2036, change +89%; Iron deficiency and imaging: USD 3.8 bn in 2026, USD 8.3 bn in 2036, change +118%.20262036 forecastChangeOncology+128%6.8 bn15.6 bnGenetic and rare disease+227%4.2 bn13.8 bnInfectious disease vaccines+89%5.2 bn9.9 bnIron deficiency and imaging+118%3.8 bn8.3 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Infectious disease vaccines26.0%20.8%USD 5.2 bn6.6%
Oncology34.0%32.7%USD 6.8 bn8.6%
Iron deficiency and imaging19.0%17.5%USD 3.8 bn8.1%
Genetic and rare disease21.0%29.0%USD 4.2 bn12.6%

By nanocarrier type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Lipid nanoparticles32.0%35.0%USD 6.4 bn10.0%
Polymeric nanoparticles22.0%21.0%USD 4.4 bn8.5%
Inorganic and metal nanoparticles18.0%16.0%USD 3.6 bn7.7%
Nanocrystals16.0%14.0%USD 3.2 bn7.5%
Dendrimers and others12.0%14.0%USD 2.4 bn10.7%

By route

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Injectable62.0%60.0%USD 12.4 bn8.6%
Oral16.0%16.0%USD 3.2 bn9.0%
Topical and transdermal12.0%12.0%USD 2.4 bn9.0%
Inhalation and ocular10.0%12.0%USD 2.0 bn11.0%

By development stage

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Marketed products58.0%50.0%USD 11.6 bn7.4%
Clinical stage30.0%34.0%USD 6.0 bn10.4%
Preclinical stage12.0%16.0%USD 2.4 bn12.2%

Top 25 countries for nanomedicine by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 90.5% of 2026 revenue and the 25 countries below together hold 97.5%.

Exhibit 4United States is the largest country market at USD 9.6 bn in 2026, and the three largest countries hold 64.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Nanomedicine market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 9.6 bn, 48.0%; Japan: USD 1.8 bn, 9.0%; China: USD 1.4 bn, 7.0%; Germany: USD 1.2 bn, 6.0%; France: USD 903 mn, 4.5%; United Kingdom: USD 803 mn, 4.0%; Italy: USD 703 mn, 3.5%; Canada: USD 602 mn, 3.0%; Spain: USD 602 mn, 3.0%; South Korea: USD 502 mn, 2.5%.United States9.6 bn 48.0%Japan1.8 bn 9.0%China1.4 bn 7.0%Germany1.2 bn 6.0%France903 mn 4.5%United Kingdom803 mn 4.0%Italy703 mn 3.5%Canada602 mn 3.0%Spain602 mn 3.0%South Korea502 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 9.6 bn48.0%USD 22.3 bn8.8%
2JapanUSD 1.8 bn9.0%USD 3.5 bn6.7%
3ChinaUSD 1.4 bn7.0%USD 4.9 bn13.3%
4GermanyUSD 1.2 bn6.0%USD 2.8 bn8.8%
5FranceUSD 903 mn4.5%USD 2.0 bn8.2%
6United KingdomUSD 803 mn4.0%USD 1.9 bn8.7%
7ItalyUSD 703 mn3.5%USD 1.6 bn8.4%
8CanadaUSD 602 mn3.0%USD 1.4 bn8.6%
9SpainUSD 602 mn3.0%USD 1.3 bn8.2%
10South KoreaUSD 502 mn2.5%USD 1.3 bn10.2%
11NetherlandsUSD 225 mn1.1%USD 542 mn9.2%
12AustraliaUSD 199 mn1.0%USD 480 mn9.2%
13SwitzerlandUSD 175 mn0.9%USD 423 mn9.2%
14BelgiumUSD 138 mn0.7%USD 333 mn9.2%
15SwedenUSD 122 mn0.6%USD 295 mn9.2%
16IndiaUSD 100 mn0.5%USD 242 mn9.2%
17MexicoUSD 82 mn0.4%USD 200 mn9.3%
18DenmarkUSD 74 mn0.4%USD 181 mn9.3%
19IsraelUSD 66 mn0.3%USD 162 mn9.3%
20TaiwanUSD 56 mn0.3%USD 138 mn9.4%
21IrelandUSD 48 mn0.2%USD 114 mn9.0%
22SingaporeUSD 40 mn0.2%USD 100 mn9.5%
23BrazilUSD 32 mn0.2%USD 76 mn9.0%
24PolandUSD 28 mn0.1%USD 67 mn9.0%
25TurkeyUSD 24 mn0.1%USD 62 mn9.9%
Rest of worldUSD 496 mn2.5%USD 1.2 bn9.2%
Exhibit 5United States and China account for 59% of the USD 27.4 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Nanomedicine market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 20.1 bn. United States: +USD 12.7 bn; China: +USD 3.5 bn; Japan: +USD 1.7 bn; Germany: +USD 1.6 bn; France: +USD 1.1 bn; 20 other countries: +USD 6.2 bn; Rest of world: +USD 702 mn. Market value 2036: USD 47.5 bn.Market value 202620.1 bnUnited States+12.7 bnChina+3.5 bnJapan+1.7 bnGermany+1.6 bnFrance+1.1 bn20 other countries+6.2 bnRest of world+702 mnMarket value 203647.5 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Pfizer
  • Moderna
  • Bristol Myers Squibb
  • Gilead Sciences
  • Johnson and Johnson

Group 2: Regional and specialist players

  • BioNTech
  • Alnylam Pharmaceuticals
  • Pacira BioSciences
  • Jazz Pharmaceuticals
  • Ipsen
  • Novavax
  • Teva

Group 3: Emerging and niche players

  • Arcturus Therapeutics
  • Acuitas Therapeutics
  • Genevant Sciences
  • Nanobiotix
  • Arbutus Biopharma

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the nanomedicine market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.

The market is divided by platform, by application, by nanocarrier type, by route, by development stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the nanomedicine market?

The global nanomedicine market is estimated at USD 18.5 bn in 2025 and USD 20.1 bn in 2026.

How fast will the nanomedicine market grow?

It is forecast to reach USD 47.5 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 27.4 bn.

Which country is the largest market for nanomedicine?

United States is the largest market by revenue at USD 9.6 bn in 2026, 48.0% of the global total. The three largest countries together hold 64.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 13.3% a year from 2026 to 2036.

Which nanomedicine segment is largest?

In the by platform split, Lipid nanoparticles is the largest segment with 36.0% of 2026 revenue.

Who are the leading nanomedicine companies?

Global leaders include Pfizer, Moderna, Bristol Myers Squibb, Gilead Sciences.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← NICU Modular Nutrition Nasal Congestion Treatment Devices →

All Healthcare markets →

Request a sample